Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0008633,
umls-concept:C0023473,
umls-concept:C0041740,
umls-concept:C0205390,
umls-concept:C0220901,
umls-concept:C0243161,
umls-concept:C0302350,
umls-concept:C0562547,
umls-concept:C1272753,
umls-concept:C1522609,
umls-concept:C1527178,
umls-concept:C1554112,
umls-concept:C1705938,
umls-concept:C1707455,
umls-concept:C2828073
|
pubmed:issue |
1-2
|
pubmed:dateCreated |
1992-6-18
|
pubmed:abstractText |
In a comparison of 47 patients with Philadelphia-chromosome (Ph)-positive chronic myeloid leukemia (CML) in the Nagasaki University School of Medicine and 64 patients with the same disease in the Roswell Park Memorial Institute, the correlation between the modal number of chromosomes and the therapeutic response and/or survival after the onset of the blastic phase (BP) was evaluated. The patients were divided into four groups on the basis of the modal number of chromosomes of the cells in the bone marrow: those with hypodiploidy (group 1), those with pseudodiploidy carrying a Ph chromosome (group 2), those with 47 chromosomes (group 3), and those with 48 or more chromosomes (group 4). The results revealed similar trends in the two institutes. Namely, the therapeutic response and the survival after the onset of the BP in groups 1 and 4 were more unfavorable and shorter than those in groups 2 and 3, although the former (group 2) had a better prognosis than the latter (group 3). Thus, the statistical analysis revealed that the numerical chromosome findings at the BP are useful parameters for assessing the therapeutic response and survival after the onset of the BP of CML.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0001-5792
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
87
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
49-53
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1585770-Adolescent,
pubmed-meshheading:1585770-Adult,
pubmed-meshheading:1585770-Aged,
pubmed-meshheading:1585770-Aged, 80 and over,
pubmed-meshheading:1585770-Blast Crisis,
pubmed-meshheading:1585770-Child,
pubmed-meshheading:1585770-Chromosome Aberrations,
pubmed-meshheading:1585770-Female,
pubmed-meshheading:1585770-Humans,
pubmed-meshheading:1585770-Japan,
pubmed-meshheading:1585770-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:1585770-Male,
pubmed-meshheading:1585770-Middle Aged,
pubmed-meshheading:1585770-Ploidies,
pubmed-meshheading:1585770-Prognosis,
pubmed-meshheading:1585770-Survival Rate,
pubmed-meshheading:1585770-United States
|
pubmed:year |
1992
|
pubmed:articleTitle |
Therapeutic and prognostic value of modal number of chromosomes at the blastic phase of Philadelphia-chromosome-positive chronic myeloid leukemia: comparison based on the same criteria between Nagasaki University and Roswell Park Memorial Institute.
|
pubmed:affiliation |
Department of Hematology, Nagasaki University School of Medicine, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|